Taletrectinib NSCLC Approval | Latest Cancer News
- The Food and Drug Administration has granted approval to taletrectinib (Ibtrozi, nuvation Bio) for the treatment of locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC).
- Taletrectinib is classified as a next-generation ROS1 TKI, distinguishing it from earlier options like crizotinib and entrectinib.
- Like repotrectinib,taletrectinib received breakthrough therapy designation from the FDA.
The FDA has approved taletrectinib (Ibtrozi) for advanced ROS1-positive non-small cell lung cancer (NSCLC), marking a significant advancement for patients battling this form of cancer. This next-generation ROS1 tyrosine kinase inhibitor (TKI) is now available for both initial and subsequent treatments,regardless of prior TKI exposure,offering new hope and potentially improved outcomes based on the TRUST-I and TRUST-II trial results. Taletrectinib shows promise with favorable brain penetration and a lower incidence of neurological side effects compared to previous options. News Directory 3 provides the latest updates on this breakthrough, including efficacy data and safety profiles from the clinical trials. Discover how this new drug could change treatment strategies and what the implications are for those with ROS1-positive NSCLC.
FDA Approves Taletrectinib for ROS1-Positive Non-Small Cell Lung cancer
The Food and Drug Administration has granted approval to taletrectinib (Ibtrozi, nuvation Bio) for the treatment of locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC). This approval extends to both first-line and subsequent treatments, irrespective of prior exposure to ROS1 tyrosine kinase inhibitors (TKIs).
Taletrectinib is classified as a next-generation ROS1 TKI, distinguishing it from earlier options like crizotinib and entrectinib. Repotrectinib, another next-generation medicine, gained approval in 2023.
Like repotrectinib,taletrectinib received breakthrough therapy designation from the FDA.
Nuvation BioS data suggests that taletrectinib offers improved brain penetration, a lower incidence of neurological side effects, reduced likelihood of resistance, and potential advantages in safety and efficacy compared to repotrectinib.
Dr. Thomas E. Stinchcombe, associate editor at the Journal of Clinical Oncology, noted that taletrectinib is likely to become the preferred treatment for advanced ROS1+ NSCLC.His comment appeared in conjunction with a pooled analysis of the TRUST-I and TRUST-II approval studies.
Taletrectinib was initially developed and approved in china in January 2025 for the same indication. Nuvation Bio anticipates launching the drug in the U.S.by mid-2025, according to a press release.
Approximately 2% of NSCLC patients exhibit ROS1-positive disease,with about one-third developing brain metastases. these patients have a rearrangement in the ROS1 gene, leading to an abnormal ROS1 fusion protein that drives cancer growth.ROS1 TKIs work by blocking the activity of this protein.
The FDA’s approval was based on the TRUST-I and TRUST-II trials, which were phase 2, single-arm, open-label studies. Patients with ROS1-positive NSCLC received 600 mg of oral taletrectinib daily until disease progression, unacceptable toxicity, death, or withdrawal of consent. The pooled analysis included 273 subjects, with 93.8% having stage IV disease, 33.7% with brain metastases, and 27.1% having received prior chemotherapy.
TRUST-I involved Chinese subjects who were either new to TKIs or had previously received crizotinib. TRUST-II included patients from North America, Europe, and Asia who were TKI-naive or had been treated with crizotinib or entrectinib.
Efficacy data came from 157 patients who had not previously received a ROS1 TKI and 113 patients who had received one prior ROS1 TKI.Prior chemotherapy for advanced disease was permitted.
In treatment-naive patients,the overall response rate (ORR) was 90% in TRUST-I and 85% in TRUST-II. The duration of response (DOR) lasted at least a year in 72% and 63% of responders, respectively. For TKI-pretreated patients, the ORR was 52% in TRUST-I and 62% in TRUST-II, with 74% and 83% of responders having a DOR of at least 6 months, respectively.
Among 13 patients with the G2032R mutation, which confers resistance to first-generation ROS1 TKIs, 61.5% responded to taletrectinib.
Safety analysis of 352 patients revealed that the most common treatment-emergent adverse events were gastrointestinal issues (88%), elevated aspartate aminotransferase (72%), and elevated alanine aminotransferase (68%). Neurological adverse events included dizziness (21%) and dysgeusia (15%). 33% of patients experienced grade 3 or higher treatment-related adverse events, leading to discontinuation in 7% of patients.Three treatment-related deaths occurred due to abnormal hepatic function, liver failure, and pneumonia.
Taletrectinib’s prescribing data includes warnings and precautions for hepatotoxicity,interstitial lung disease/pneumonitis,QTc interval prolongation,hyperuricemia,myalgia with creatine phosphokinase elevation,skeletal fractures,and embryo-fetal toxicity.
The recommended dose is 600 mg orally once daily on an empty stomach until disease progression or unacceptable toxicity.
Pricing for taletrectinib is not yet available. For comparison, a two-week supply of repotrectinib costs $7,666.97, according to drugs.com.
What’s next
Nuvation Bio plans to launch taletrectinib in the U.S. by mid-2025,offering a new treatment option for patients with ROS1-positive non-small cell lung cancer.